233 related articles for article (PubMed ID: 15472203)
21. Altered tumor necrosis factor alpha release from mononuclear cells of obese reproductive-age women during hyperglycemia.
González F; Minium J; Rote NS; Kirwan JP
Metabolism; 2006 Feb; 55(2):271-6. PubMed ID: 16423637
[TBL] [Abstract][Full Text] [Related]
22. Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary manipulation in obese and nonobese subjects.
Kelijman M; Frohman LA
J Clin Endocrinol Metab; 1988 Mar; 66(3):489-94. PubMed ID: 3127415
[TBL] [Abstract][Full Text] [Related]
23. The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects.
James AP; Watts GF; Mamo JC
Diabetes Obes Metab; 2005 Jul; 7(4):381-9. PubMed ID: 15955124
[TBL] [Abstract][Full Text] [Related]
24. Lipase maturation factor 1: its expression in Zucker diabetic rats, and effects of metformin and fenofibrate.
Forcheron F; Basset A; Del Carmine P; Beylot M
Diabetes Metab; 2009 Dec; 35(6):452-7. PubMed ID: 19854668
[TBL] [Abstract][Full Text] [Related]
25. Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.
Brunani A; Caumo A; Graci S; Castagna G; Viberti G; Liuzzi A
Diabetes Obes Metab; 2008 Jun; 10(6):460-7. PubMed ID: 17394563
[TBL] [Abstract][Full Text] [Related]
26. Effect of obesity on ambient plasma glucose, free fatty acid, insulin, growth hormone, and glucagon concentrations.
Golay A; Swislocki AL; Chen YD; Jaspan JB; Reaven GM
J Clin Endocrinol Metab; 1986 Aug; 63(2):481-4. PubMed ID: 3522620
[TBL] [Abstract][Full Text] [Related]
27. Plasma free fatty acid concentration during hyperglycemic glucose clamp with and without somatostatin infusion in obese subjects with normal glucose tolerance.
Zancanaro C; Cigolini M; Bonora E; Moghetti P; Cacciatori V; Querena M; Muggeo M
Int J Obes; 1990 Jul; 14(7):551-7. PubMed ID: 1977721
[TBL] [Abstract][Full Text] [Related]
28. Effects of a combination of rhGH and metformin on adiponectin levels in patients with metabolic syndrome.
Herrmann BL; Saller B; Stratmann M; Berg C; Mann K; Janssen OE
Horm Metab Res; 2005 Jan; 37(1):49-52. PubMed ID: 15702440
[TBL] [Abstract][Full Text] [Related]
29. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Ortega-González C; Luna S; Hernández L; Crespo G; Aguayo P; Arteaga-Troncoso G; Parra A
J Clin Endocrinol Metab; 2005 Mar; 90(3):1360-5. PubMed ID: 15598674
[TBL] [Abstract][Full Text] [Related]
30. Tissue factor expression in obese type 2 diabetic subjects and its regulation by antidiabetic agents.
Wang J; Ciaraldi TP; Samad F
J Obes; 2015; 2015():291209. PubMed ID: 25861467
[TBL] [Abstract][Full Text] [Related]
31. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
Singh S; Akhtar N; Ahmad J
Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540
[TBL] [Abstract][Full Text] [Related]
32. Intramyocellular triglyceride content in man, influence of sex, obesity and glycaemic control.
Haugaard SB; Mu H; Vaag A; Madsbad S
Eur J Endocrinol; 2009 Jul; 161(1):57-64. PubMed ID: 19417077
[TBL] [Abstract][Full Text] [Related]
33. [Effect of metformin on the expression of tumor necrosis factor-α, Toll like receptors 2/4 and C reactive protein in obese type-2 diabetic patients].
Andrews M; Soto N; Arredondo M
Rev Med Chil; 2012 Nov; 140(11):1377-82. PubMed ID: 23677182
[TBL] [Abstract][Full Text] [Related]
34. Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity.
McLaughlin T; Abbasi F; Lamendola C; Kim HS; Reaven GM
Metabolism; 2001 Jul; 50(7):819-24. PubMed ID: 11436188
[TBL] [Abstract][Full Text] [Related]
35. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin.
Srinivasan S; Ambler GR; Baur LA; Garnett SP; Tepsa M; Yap F; Ward GM; Cowell CT
J Clin Endocrinol Metab; 2006 Jun; 91(6):2074-80. PubMed ID: 16595599
[TBL] [Abstract][Full Text] [Related]
36. Effect of obesity on susceptibility to fatty acid-induced peripheral tissue insulin resistance.
Kruszynska YT; Olefsky JM; Frias JP
Metabolism; 2003 Feb; 52(2):233-8. PubMed ID: 12601639
[TBL] [Abstract][Full Text] [Related]
37. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
[TBL] [Abstract][Full Text] [Related]
38. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
[TBL] [Abstract][Full Text] [Related]
39. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
[TBL] [Abstract][Full Text] [Related]
40. Metformin increases insulin sensitivity and plasma beta-endorphin in human subjects.
Ou HY; Cheng JT; Yu EH; Wu TJ
Horm Metab Res; 2006 Feb; 38(2):106-11. PubMed ID: 16523411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
